Introducing the already diluted formulation of JETREA® with a simplified preparation process to save time and eliminate the potential for dilution variability.1
©2017 ThromboGenics, Inc. All rights reserved.
ThromboGenics, Inc., 101 Wood Avenue South, Suite 610, Iselin, NJ 08830 - USA.
JETREA and the JETREA logo, JETREA CARE and the CARE logo, and THROMBOGENICS and
the THROMBOGENICS logo are trademarks or registered trademarks of ThromboGenics NV.
10/2017 OCRVMA0283 r1
JETREA® (ocriplasmin) injection, for Intravitreal Injection, 1.25mg/mL is a proteolytic enzyme indicated for the treatment of symptomatic vitreomacular adhesion.
To report SUSPECTED ADVERSE REACTIONS, contact ThromboGenics Inc. at 1-855-253-7396 [OPTION 2] or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
You may also report side effects of JETREA online directly to ThromboGenics by clicking here if you are a Patient or here if you are a Health Care Professional.
©2017 ThromboGenics, Inc. All rights reserved.
ThromboGenics, Inc., 101 Wood Avenue South, Suite 610, Iselin, NJ 08830 - USA.
JETREA and the JETREA logo, JETREA CARE and the CARE logo, and THROMBOGENICS and
the THROMBOGENICS logo are trademarks or registered trademarks of ThromboGenics NV.
10/2017 OCRVMA0283 r1